Endostatin: An endogenous inhibitor of angiogenesis and tumor growth

Cell

Volumn 88, Issue 2, 1997, Pages 277-285

  O'Reilly, Michael S ^a   Boehm, Thomas ^a   Shing, Yuen ^a   Fukai, Naomi ^b   Vasios, George ^c   Lane, William S ^d   Flynn, Evelyn ^a   Birkhead, James R ^c   Olsen, Bjorn R ^b   Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d OsteoArthritis Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE FACTOR 4;

AMINO ACID SEQUENCE; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; ENDOTHELIUM CELL; GROWTH INHIBITION; HEMANGIOENDOTHELIOMA; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN ISOLATION; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION;

EID: 0031454617     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81848-6     Document Type: Article

References (41)

1. Angiolillo, A.L., Sgadari, C., Taub, D.D., Liao, F., Farber, J.M., Miaheshwari, S., Kleinman, H.K., Reaman, G.H., and Tosato, G. (1995). Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182, 155-162.
2. Cao, Y., Chen, C., Weatherbee, J.A., Tsang, M., and Folkman, J. (1995). Gro-beta, a C-X-C chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinomain mice. J. Exp. Med. 182, 2069-2077.
3. Cao, Y., Ji, R.W., Davidson, D., Schaller, J., Marti, D., Söhndel, S., McCance, S.G., O'Reilly, M.S., Llinás, M., and Folkman, J. (1996). Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 277, 29461-29467.
4. Chen, C., Parangi, S., Tolentino, M.J., and Folkman, J. (1995). A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res. 55, 4230-4233.
5. Clapp, C., Martial, J.A., Guzman, R.C., Rentier-Delrue, F., and Weiner, R.I. (1993). The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133, 1292-1299.
6. Dameron, K.M., Volpert, O.V., Tainsky, M.A., and Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
7. Folkman, J. (1985). Angiogenesis and its inhibitors. In Important Advances in Oncology 1985, V.T. DeVita, S. Hellman, and S. Rosenberg, eds. (Philadelphia: J. B. Lippincott Company), pp. 42-62.
8. Folkman, J. (1989). What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82, 4-6.
9. Folkman, J. (1996). Tumor angiogenesis and tissue factor. Nature Med. 2, 167-168.
10. Folkman, J., Haundenschild, C.C., and Zetter, B.R. (1979). Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. USA 76, 5217-5221.
11. Gately, S., Twardowski, P., Stack, M.S., Patrick, M., Boggio, L., Cundiff, D.L., Schnaper, H.W., Madison, L., Volpert, O., Bouck, N., Enghild, J., Kwaan, H.C., and Soff, G.A. (1996). Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56, 4887-4990.
12. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119, 493-501.
13. Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S., Frazier, W.A., and Bouck, N.P. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Nat. Acad. Sci. USA. 87, 6624-6628.
14. Grant, D.S., Tashiro, K.-I., Sequi-Real, B., Yamada, Y., Martin, G.R., and Kleinman, H.K. (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58, 933-943.
15. Gross, J.L., Moscatelli, D., and Rifkin, D.B. (1983). Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc. Natl. Acad. Sci. USA 80, 2623-2627.
16. Gupta, S.K., Hassel, T., and Singh, J.P. (1995). A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc. Natl. Acad. Sci. USA 92, 7799-7803.
17. Holmgren, L., O'Reilly, M.S., and Folkman, J. (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149-153.
18. Homandberg, G.A., Williams, J.E., Grant, D.B.S., and Eisenstein, R. (1985). Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am. J. Path. 120, 327-332.
19. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., and Kozai, Y. (1991). Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 51, 6180-6184.
20. Kandel, J., Bossy-Wetzel, E., Radvany, F., Klagsburn, M., Folkman, J., and Hanahan, D. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66, 1095-1104.
21. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841-844.
22. Maione, T.E., Gray, G.S., Petro, J., Hunt, A.J., Donner, A.L., Bauer, S.I., Carson, H.F., and Sharpe, R.J. (1990). Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247, 77-79.
23. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994).Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
24. Muragaki, Y., Timmons, S., Griffith, C.M., Oh, S.P., Fadel, B., Quertermous, T., and Olsen, B.R. (1995). Mouse col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc. Natl. Acad. Sci. USA 92, 8763-8767.
25. Nelson, J., Allen, W.E., Scott, W.N., Bailie, J.R., Walker, B., and McFerran, N.V. (1995). Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF-and laminin-dependent endothelial cell motility and angiogenesis. Cancer Res. 55, 3772-3776.
26. Nguyen, M., Shing, Y., and Folkman, J. (1994). Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvascular Res. 47, 31-40.
27. Obeso, J., Weber, J., and Auerbach, R. (1990). A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. Lab. Invest. 63, 259-269.
28. Oh, S.K., Kamagata, Y., Muragaki, Y., Timmons, S., Ooshima, A., and Olsen, B.R. (1994). Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc. Natl. Acad. Sci. USA 91, 4229-4233.
29. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
30. O'Reilly, M.S., Holmgren, L., Chen, C.C., and Folkman, J. (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692.
31. Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., and Hanahan, D. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. Natl. Acad. Sci. USA 93, 2002-2007.
32. Rastinejad, F., Polverini, P.J., and Bouck, N.P. (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56, 345-355.
33. Rehn, M., and Pihlajaniemi, T. (1994). a1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc. Natl. Acad. Sci. USA 91, 4234-4238.
34. Rehn, M.,and Pihlajaniemi, T. (1995). Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. J. Biol. Chem. 270, 4705-4711.
35. Sage, E.H., Bassuk, J.A., Vost, J.C., Folkman, M.J., and Lane, T.F. (1995). Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca (2+)-binding EF-hand sequence. J. Cell Biochem. 57, 127-140.
36. Sakamato, N., Iwahana, M., Tanaka, N.G., and Osaka, Y. (1991). Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2. Cancer Res. 51, 903-906.
37. Strieter, R.M., Kunkel, S.L., Arenberg, D.A., Burdick, M.D., and Polverini, P.J. (1995). Human interferon-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Comm. 210, 51-57.
38. Studier, W.F., Rosenberg, A.H., Dunn, J.J., and Dudendorf, J.W. (1990). Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol. 85, 60-89.
39. Teicher, B.A., Holden, S.A., Ara, G., Sotomayor, E.A., and Dong, H.Z. (1994). Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int. J. Cancer 57, 1-6.
40. Tolsma, S.S., Volpert, O.V., Good, D.J., Frazier, W.A., Polverini, P.J., and Bouck, N. (1993). Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity. J. Cell Biol. 122, 497-511.
41. Voest, E.E., Kenyon, B.M., O'Reilly, M.S., Truitt, G., D'Amato, R.J., and Folkman, J. (1995). Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581-586.